Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Richard F. Pops | Chairman & CEO | 2.61M | -- | 1962 |
| Mr. Blair C. Jackson | Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO | 1.17M | -- | 1973 |
| Mr. David Joseph Gaffin J.D. | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 1.15M | -- | 1972 |
| Mr. Iain Michael Brown | Senior VP & CFO | 950.88k | -- | 1969 |
| Dr. Craig C. Hopkinson M.D. | Executive VP of Research & Development and Chief Medical Officer | 1.24M | -- | 1969 |
| Mr. Samuel J. Parisi | Interim Principal Accounting Officer & VP of Finance | -- | -- | 1975 |
| Mr. Thomas Harvey | Chief Information Officer & Senior VP of IT | -- | -- | -- |
| Ms. Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations | -- | -- | -- |
| Mr. Stephen Schiavo | Senior VP & Chief Human Resources Officer | -- | -- | -- |
| Mr. Peter Norman | Senior Vice President of Policy & Government Relations | -- | -- | -- |
Alkermes plc
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 1,800
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Corporate Governance
Upcoming Events
April 29, 2025 at 12:30 PM UTC - May 5, 2025 at 12:30 PM UTC
Alkermes plc Earnings Date